Zobrazeno 1 - 10
of 100
pro vyhledávání: '"A, Antilli"'
Autor:
L. Portalone, Anna Rita Cruciani, Franco Salvati, N Perrone, Francesco Nunziati, A. Lombardi, Antonio Antilli, V Magliacani, L Mugnaini, Mauro Signora
Publikováno v:
Tumori Journal. 85:239-242
Aims and Background The polychemotherapeutic regimen PEV (cisplatin, epidoxorubicin and vindesine) + lonidamine proved to be valid in terms of activity and efficacy in the treatment of patients with advanced, previously untreated non-small cell lung
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::778ab94307205fabc81df1e1a7c225f3
https://doi.org/10.1177/030089169908500405
https://doi.org/10.1177/030089169908500405
Autor:
Sante Barbera, Luca Boni, Adolfo Favaretto, Editta Baldini, Riccardo Rosso, Federico Castiglioni, Franca Pari, Alfonso M. Altieri, L. Tixi, Adriano Paccagnella, G Cacciani, Micaela Stefani, Paola Antonelli, Antonio Antilli, Carmelo Tibaldi, Andrea Ardizzoni, Mario Raimondi, Silvio Monfardini
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(3)
Purpose Small-cell lung cancer (SCLC) is increasingly diagnosed in elderly patients, who are at higher risk of treatment-related morbidity and mortality. We conducted a randomized two-stage phase II study to assess the therapeutic index of two differ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1eba138892e3ddb18bca1c3c5e8a6663
https://pubmed.ncbi.nlm.nih.gov/15659503
https://pubmed.ncbi.nlm.nih.gov/15659503
Autor:
M. Crippa, Noseda Ma, Elizabeth H. Baldini, Antilli A, Sunseri G, Carmelo Tibaldi, Cacciani Gc, Romano F, R. Rosso, Andrea Ardizzoni, Borghini U, M. Bandera, Galeasso G, Lepidini G, S. Barbera, L. Portalone, C. Lanfranco, Rinaldi M, M. Fioretti, Salvati F, M. Raimondi, M. C. Pennucci, Migliorino Mr, De Marinis F, G. B. Ferrara
Publikováno v:
British Journal of Cancer. 77:2367-2370
In the present multicentre randomized phase II trial, the activity and toxicity of three platinum-based combination regimens for the treatment of advanced non-small-cell lung cancer (NSCLC) were evaluated. The three regimens were: MVP (mitomycin-C 6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::230e36e00e392af480acbca947728a42
https://doi.org/10.1038/bjc.1998.393
https://doi.org/10.1038/bjc.1998.393
Autor:
O. Daniele, Andrea Lissoni, A. Antonuzzo, A. Maestri, P. Anastasi, Arcispedale S. Anna Ferrara, C. Basurto, Stefano Cascinu, S. Ramponi, M. Tagliaventi, V. Silingardi, E. Mantellim, G. Scagliotti, Fausto Roila, S. Ricci, D. Donati, F. Meriggi, M. Tonato, R. Tonachella, F. Di Costanzo, A. Santoro, M. Federico, E. Riva, P. Malacarne, Francesco Cognetti, A. Fabi, S. Tateo, M. Picciafuoco, A. D'Antona, G. Ferretti, A. Del Favero, F. Salvati, C. Boni, F. Nunziati, V. Ferraresi, M. A. Palladino, A. M. Mosconi, R. Sabbatini, Silvana Chiara, P. Zucchinelli, Elisabetta Campora, A. Antilli, A. Zaniboni, Pierfranco Conte, P. Barbian, G. Moretti, M. C. Locatelli, Enrico Cortesi, Giacomo Allegrini, V. De Angelis, G. Catalano, A. Trassoldati, S. Cirulli, Enzo Ballatori, G. Ciccarese
Publikováno v:
Annals of Oncology. 8:561-567
Summary Background The pattern and prognostic factors of delayed nausea and vomiting induced by moderately emetogenic chemotherapy have not yet been adequately studied. Patients and methods Data are derived from a large and well defined population of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8bf8f3091e2d3f7928a3a72eed02162a
https://doi.org/10.1023/a:1008229721099
https://doi.org/10.1023/a:1008229721099
Autor:
Marina Fioretti, Enzo Soresi, Paolo Bruzzi, F. Salvati, Filippo de Marinis, Santi Barbera, Riccardo Rosso, Marco Venturini, M. C. Pennucci, Giovanni Pallotta, Gisella Pastorino, Leonardo Santi, Ennio Mantellini, Mario Belli, Anna Maria Cruciani, Giorgio V. Scagliotti, R. Tonachella, Giuseppe Ferrara, Gabriella Mariani, Andrea Ardizzoni, Alessandra Rubagotti, Antonio Antilli, M. Rinaldi
Publikováno v:
Cancer. 72:2929-2935
BACKGROUND Preclinical data suggested that alpha-interferon (IFN) may potentiate chemotherapy cytotoxicity. METHODS A prospective multicentric randomized trial was initiated to assess the clinical benefit of adding recombinant alpha-2-IFN to combinat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::821f5273dc57a029c0e9820626449c31
https://doi.org/10.1002/1097-0142(19931115)72:10<2929::aid-cncr2820721012>3.0.co
https://doi.org/10.1002/1097-0142(19931115)72:10<2929::aid-cncr2820721012>3.0.co
Autor:
C. Fortini, M. Crippa, G. Genovese, Editta Baldini, A. R. Cruciani, Andrea Ardizzoni, Antilli A, F. Salvati, G. Scagliotti, M. Rinaldi, E. Soresi, E. Gatti, C Pennucci, R. Tonachella, R. Rosso, G. B. Ferrara
Publikováno v:
American Journal of Clinical Oncology. 14:120-123
Thirty-four patients with previously untreated advanced non-small-cell lung cancer were treated with a combination of polychemotherapy and recombinant interferon. Chemotherapy consisted of cyclophosphamide, 400 mg/m2, epidoxorubicin, 50 mg/m2, and ci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a1717d1ad502bcd1d3ee8e6d814fed0
https://doi.org/10.1097/00000421-199104000-00005
https://doi.org/10.1097/00000421-199104000-00005
Autor:
Filippo Demarinis, Paolo Pronzato, Domenico Sambiasi, Luigi Portalone, A. Lombardi, Luigi Friggeri, Carlo Crispino, Vito Lorusso, Mauro Signora, Antonio Antilli, Francesco Nunziati
Publikováno v:
Scopus-Elsevier
Malignant pleural mesothelioma represents a rare disease, for which chemotherapy actually remains unsatisfactory. From August 1998 to November 2001, 28 chemo-radio-immunonaive patients were consecutively enrolled in the trial: 22/6 males/females; med
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63223f8bf2f30d2bd90efb57858ec358
https://pubmed.ncbi.nlm.nih.gov/15849999
https://pubmed.ncbi.nlm.nih.gov/15849999
Autor:
E, Baldini, C, Tibaldi, A, Ardizzoni, F, Salvati, A, Antilli, L, Portalone, S, Barbera, F, Romano, F, De Marinis, M R, Migliorino, M A, Noseda, U, Borghini, M, Crippa, G, Ferrara, M, Raimondi, M, Fioretti, M, Bandera, M C, Pennucci, G, Galeasso, G C, Cacciani, G, Lepidini, G, Sunseri, C, Lanfranco, M, Rinaldi, R, Rosso
Publikováno v:
British Journal of Cancer
In the present multicentre randomized phase II trial, the activity and toxicity of three platinum-based combination regimens for the treatment of advanced non-small-cell lung cancer (NSCLC) were evaluated. The three regimens were: MVP (mitomycin-C 6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3db9703b2d89077ab798a95f15578d81
https://pubmed.ncbi.nlm.nih.gov/9649160
https://pubmed.ncbi.nlm.nih.gov/9649160
Publikováno v:
Anticancer research. 16(2)
22 patients with advanced non-small-cell lung cancer were randomized to receive chemotherapy (ifosfamide) or chemotherapy followed by thymosin alpha1 + low-dose IFNalpha. Chemo-immunotherapy induced an enhanced response rate compared with chemotherap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d3d71d21717fcdd2a3b52f2f4ae0c035
https://pubmed.ncbi.nlm.nih.gov/8687090
https://pubmed.ncbi.nlm.nih.gov/8687090